Since Morphic’s founding in 2003, our mission has been to alleviate the symptoms of obesity for patients fighting cardiometabolic disease in our current global epidemic.
Our technology, RESET ® therapy, is a testament to Morphic’s mission. The first endoscopically delivered duodenal device therapy for the treatment of obesity. The RESET® therapy is a new treatment option to support the fight against obesity for people with at least one cardiometabolic risk factor, primarily type 2 diabetes or dyslipidemia. RESET® is a minimally invasive and temporary device which covers an unmet medical need for patients not ready to undergo permanent bariatric surgery but in need of a bariatric intervention.
Morphic is headquartered in Boston, Massachusetts, with an international office in Berlin, Germany. Our team of business experts and industry veterans have a successful track record of pioneering and commercializing breakthrough healthcare technologies.
23% of adults were estimated to have obesity and 36% pre-obesity in the European Union in 2016 1
Obesity is the highest independent cause of premature mortality 3
10% - 13% of deaths in different parts of Europe are linked to obesity 2
7% of the national budgets across the EU is spent on non-communicable diseases associated with obesity every year 1
